143 related articles for article (PubMed ID: 11915176)
1. Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response.
Meredith R
Cancer Biother Radiopharm; 2002 Feb; 17(1):83-99. PubMed ID: 11915176
[TBL] [Abstract][Full Text] [Related]
2. Risks to normal tissues from radionuclide therapy.
Meredith R; Wessels B; Knox S
Semin Nucl Med; 2008 Sep; 38(5):347-57. PubMed ID: 18662556
[TBL] [Abstract][Full Text] [Related]
3. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
6. [Side effects evaluation of ionizing radiation].
Pointreau Y; Kreps S; Hennequin C
Cancer Radiother; 2010 Jul; 14(4-5):246-9. PubMed ID: 20615744
[TBL] [Abstract][Full Text] [Related]
7. Normal tissue tolerance dose metrics for radiation therapy of major organs.
Milano MT; Constine LS; Okunieff P
Semin Radiat Oncol; 2007 Apr; 17(2):131-40. PubMed ID: 17395043
[TBL] [Abstract][Full Text] [Related]
8. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017.
Okunieff P; Casey-Sawicki K; Lockney NA; Hoppe BS; Enderling H; Pinnix C; Welsh J; Krishnan S; Yothers G; Brown M; Knox S; Bristow R; Spellman P; Mitin T; Nabavizadeh N; Jaboin J; Manning HC; Feng F; Galbraith S; Solanki AA; Harkenrider MM; Tuli R; Decker RH; Finkelstein SE; Hsu CC; Ha CS; Jagsi R; Shumway D; Daly M; Wang TJC; Fitzgerald TJ; Laurie F; Marshall DT; Raben D; Constine L; Thomas CR; Kachnic LA
Clin Cancer Res; 2018 Aug; 24(15):3500-3509. PubMed ID: 29661779
[TBL] [Abstract][Full Text] [Related]
9. Normal tissue tolerance and damage.
Cancer; 1976 Apr; 37(4 Suppl):2046-55. PubMed ID: 1260701
[No Abstract] [Full Text] [Related]
10. [Dosimetric factors predictive of late toxicity in prostate cancer radiotherapy].
de Crevoisier R; Fiorino C; Dubray B
Cancer Radiother; 2010 Oct; 14(6-7):460-8. PubMed ID: 20797890
[TBL] [Abstract][Full Text] [Related]
11. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
12. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data.
Semenenko VA; Li XA
Phys Med Biol; 2008 Feb; 53(3):737-55. PubMed ID: 18199912
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of the pathological changes induced by radiotherapy in normal tissues.
Rezvani M
J Pharm Pharmacol; 2008 Aug; 60(8):1037-48. PubMed ID: 18644196
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry of internal emitters.
Sgouros G
J Nucl Med; 2005 Jan; 46 Suppl 1():18S-27S. PubMed ID: 15653648
[TBL] [Abstract][Full Text] [Related]
15. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
16. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
17. Patient safety in external beam radiation therapy.
Yorke E; Gelblum D; Ford E
AJR Am J Roentgenol; 2011 Apr; 196(4):768-72. PubMed ID: 21427323
[TBL] [Abstract][Full Text] [Related]
18. Treatment planning for molecular targeted radionuclide therapy.
Siantar CH; Vetter K; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):267-80. PubMed ID: 12136519
[TBL] [Abstract][Full Text] [Related]
19. Renal dosimetry in peptide radionuclide receptor therapy.
Siegel JA; Stabin MG; Sharkey RM
Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
[TBL] [Abstract][Full Text] [Related]
20. [Normal tissue tolerance to external beam radiation therapy: bone marrow].
Drouet F; Lagrange JL
Cancer Radiother; 2010 Jul; 14(4-5):392-404. PubMed ID: 20598617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
